These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33041002)

  • 1. Trimebutine attenuates high mobility group box 1-receptor for advanced glycation end-products inflammatory signaling pathways.
    Nakajima S; Ogawa N; Yokoue N; Tachibana H; Tamada K; Okazawa M; Sato A; Oyama T; Abe H; Kamiya T; Yoshimori A; Yoshizawa K; Inoue S; Yokomizo T; Uchiumi F; Abe T; Tanuma SI
    Biochem Biophys Res Commun; 2020 Dec; 533(4):1155-1161. PubMed ID: 33041002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 3-styrylchromone converted from trimebutine 3D pharmacophore possesses dual suppressive effects on RAGE and TLR4 signaling pathways.
    Okazawa M; Oyama T; Abe H; Yamazaki H; Yoshimori A; Tsukimoto M; Yoshizawa K; Takao K; Sugita Y; Kamiya T; Uchiumi F; Sakagami H; Abe T; Tanuma SI
    Biochem Biophys Res Commun; 2021 Aug; 566():1-8. PubMed ID: 34111666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimebutine suppresses Toll-like receptor 2/4/7/8/9 signaling pathways in macrophages.
    Ogawa N; Nakajima S; Tamada K; Yokoue N; Tachibana H; Okazawa M; Oyama T; Abe H; Yamazaki H; Yoshimori A; Sato A; Kamiya T; Yokomizo T; Uchiumi F; Abe T; Tanuma SI
    Arch Biochem Biophys; 2021 Oct; 711():109029. PubMed ID: 34517011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses.
    Tamada K; Nakajima S; Ogawa N; Inada M; Shibasaki H; Sato A; Takasawa R; Yoshimori A; Suzuki Y; Watanabe N; Oyama T; Abe H; Inoue S; Abe T; Yokomizo T; Tanuma S
    Biochem Biophys Res Commun; 2019 Apr; 511(3):665-670. PubMed ID: 30826057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Dual Anti-Inflammatory and Anti-Proliferative 3-Styrylchromone Derivative Synergistically Enhances the Anti-Cancer Effects of DNA-Damaging Agents on Colon Cancer Cells by Targeting HMGB1-RAGE-ERK1/2 Signaling.
    Tanuma SI; Oyama T; Okazawa M; Yamazaki H; Takao K; Sugita Y; Amano S; Abe T; Sakagami H
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMGB1 binding to receptor for advanced glycation end products enhances inflammatory responses of human bronchial epithelial cells by activating p38 MAPK and ERK1/2.
    Liang Y; Hou C; Kong J; Wen H; Zheng X; Wu L; Huang H; Chen Y
    Mol Cell Biochem; 2015 Jul; 405(1-2):63-71. PubMed ID: 25862459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production and application of HMGB1 derived recombinant RAGE-antagonist peptide for anti-inflammatory therapy in acute lung injury.
    Lee S; Piao C; Kim G; Kim JY; Choi E; Lee M
    Eur J Pharm Sci; 2018 Mar; 114():275-284. PubMed ID: 29292016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Mobility Group Box 1 Is Associated with the Inflammatory Pathogenesis of Graves' Orbitopathy.
    Han SY; Choi SH; Shin JS; Lee EJ; Han SH; Yoon JS
    Thyroid; 2019 Jun; 29(6):868-878. PubMed ID: 30973094
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-high-mobility group box-1 (HMGB1) mediates the apoptosis of alveolar epithelial cells (AEC) by receptor of advanced glycation end-products (RAGE)/c-Jun N-terminal kinase (JNK) pathway in the rats of crush injuries.
    Zhang BF; Song W; Wang J; Wen PF; Zhang YM
    J Orthop Surg Res; 2022 Jan; 17(1):20. PubMed ID: 35033142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A murine cellular model of necroinflammation displays RAGE-dependent cytokine induction that connects to hepatoma cell injury.
    Bachmann M; Lamprecht L; Gonther S; Pfeilschifter J; Mühl H
    J Cell Mol Med; 2020 Sep; 24(18):10356-10366. PubMed ID: 32697038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expatiating the molecular approaches of HMGB1 in diabetes mellitus: Highlighting signalling pathways via RAGE and TLRs.
    Behl T; Sharma E; Sehgal A; Kaur I; Kumar A; Arora R; Pal G; Kakkar M; Kumar R; Bungau S
    Mol Biol Rep; 2021 Feb; 48(2):1869-1881. PubMed ID: 33479829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Mobility Group Box 1 (HMGB1) Induces Migration of Endothelial Progenitor Cell via Receptor for Advanced Glycation End-Products (RAGE)-Dependent PI3K/Akt/eNOS Signaling Pathway.
    Zhang Y; You B; Liu X; Chen J; Peng Y; Yuan Z
    Med Sci Monit; 2019 Aug; 25():6462-6473. PubMed ID: 31461437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice.
    Ge X; Arriazu E; Magdaleno F; Antoine DJ; Dela Cruz R; Theise N; Nieto N
    Hepatology; 2018 Dec; 68(6):2380-2404. PubMed ID: 29774570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMGB1/RAGE pro-inflammatory axis promotes vascular endothelial cell apoptosis in limb ischemia/reperfusion injury.
    Mi L; Zhang Y; Xu Y; Zheng X; Zhang X; Wang Z; Xue M; Jin X
    Biomed Pharmacother; 2019 Aug; 116():109005. PubMed ID: 31136947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
    Nguyen AH; Detty SQ; Agrawal DK
    Anticancer Res; 2017 Jan; 37(1):1-7. PubMed ID: 28011467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketamine attenuates sepsis-induced acute lung injury via regulation of HMGB1-RAGE pathways.
    Li K; Yang J; Han X
    Int Immunopharmacol; 2016 May; 34():114-128. PubMed ID: 26945830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Unique Anti-Cancer 3-Styrylchromone Suppresses Inflammatory Response via HMGB1-RAGE Signaling.
    Abe H; Okazawa M; Oyama T; Yamazaki H; Yoshimori A; Kamiya T; Tsukimoto M; Takao K; Sugita Y; Sakagami H; Abe T; Tanuma SI
    Medicines (Basel); 2021 Mar; 8(4):. PubMed ID: 33805209
    [No Abstract]   [Full Text] [Related]  

  • 18. High-mobility group box 1 promotes extracellular matrix synthesis and wound repair in human bronchial epithelial cells.
    Ojo OO; Ryu MH; Jha A; Unruh H; Halayko AJ
    Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(11):L1354-66. PubMed ID: 26432865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation.
    Yang H; Liu H; Zeng Q; Imperato GH; Addorisio ME; Li J; He M; Cheng KF; Al-Abed Y; Harris HE; Chavan SS; Andersson U; Tracey KJ
    Mol Med; 2019 Apr; 25(1):13. PubMed ID: 30975096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease.
    Chandrashekaran V; Seth RK; Dattaroy D; Alhasson F; Ziolenka J; Carson J; Berger FG; Kalyanaraman B; Diehl AM; Chatterjee S
    Redox Biol; 2017 Oct; 13():8-19. PubMed ID: 28551086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.